EphA2 Receptor

An Eph family receptor found abundantly in tissues of epithelial origin. It is expressed in a diverse array of tissues during embryonic development, suggesting that it may play a role in embryogenesis. In adult tissues high levels of the receptor are expressed in the LUNG; SKIN; SMALL INTESTINE and OVARY.

Also Known As:

Networked: 229 relevant articles (4 outcomes, 31 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Kinch, Michael S: 15 articles (06/2011 - 01/2002)
2.	Chen, Jin: 14 articles (11/2020 - 10/2002)
3.	Pasquale, Elena B: 13 articles (03/2022 - 12/2002)
4.	Pellecchia, Maurizio: 9 articles (10/2020 - 12/2008)
5.	Leone, Marilisa: 8 articles (01/2020 - 12/2008)
6.	Brantley-Sieders, Dana M: 7 articles (01/2021 - 11/2005)
7.	Debinski, Waldemar: 7 articles (01/2021 - 12/2007)
8.	Marasco, Daniela: 6 articles (01/2020 - 03/2012)
9.	Pirone, Luciano: 6 articles (01/2020 - 03/2012)
10.	Mohammed, Kamal A: 6 articles (08/2016 - 11/2006)

Related Diseases

1.	Neoplasms (Cancer) 12/01/2023 - "Both in vitro and in vivo targeting studies showed high uptake of the construct to GBM tumors with an upregulated EphA2 receptor (T98G and U251) compared to a tumor that had low expression (U87MG), where a dual tumor xenograft model was used to demonstrate the enhanced accumulation in tumor tissue in vivo. " 01/01/2018 - "Although our studies indicated that YSA- and 123B9-drug conjugates can selectively deliver cytotoxic drugs to cancer cells in vivo, the relatively low cellular agonistic activities (i.e., the high micromolar concentrations required) of the agents toward the EphA2 receptor remained a limiting factor to the further development of these PDCs in the clinic. " 07/09/2015 - "In the present study, we focus on EphA2 receptor tyrosine kinase, which is overexpressed in many human cancers. " 03/08/2012 - "We believe these studies open the way to the development of a new class of therapeutic compounds that exploit the EphA2 receptor for drug delivery to cancer cells." 01/01/2003 - "In Recent studies have demonstrated that the EphA2 receptor tyrosine kinase is frequently overexpressed and functionally altered in aggressive tumor cells, and that these changes promote metastatic character. "
2.	Hepatocellular Carcinoma (Hepatoma) 01/01/2020 - "This strategy has been preliminarily tested by using a model system of heterotypic SAM-SAM interactions involving the erythropoietin-producing hepatoma kinase A2 (EphA2) receptor and implementing a multidisciplinary plan made up of computational docking studies, experimental interaction assays (by NMR spectroscopy and surface plasmon resonance techniques) and conformational analysis (by NMR spectroscopy and circular dichroism). " 01/01/2022 - "Erythropoietin-producing hepatoma receptor A2 (EphA2), receptor tyrosine kinase, the most widespread member of the largest receptor tyrosine kinase family, plays a critical role in physiological and pathological conditions. " 01/01/2021 - "To develop an effective treatment, we aimed at improving the suboptimal antitumor efficacy of oncolytic adenoviruses (OAs) by testing the combination with a gene-therapy approach using a bispecific T-cell engager (BiTE) directed towards the erythropoietin-producing human hepatocellular carcinoma A2 receptor (EphA2), conveyed by a replication-incompetent adenoviral vector (EphA2 adenovirus (EAd)). " 11/01/2017 - "The erythropoietin-producing hepatoma A2 receptor (EphA2) is a tyrosine kinase overexpressed by tumor stroma and cancer cells. " 02/15/2010 - "EFNA1 ligand and its receptor EphA2: potential biomarkers for hepatocellular carcinoma."
3.	Pancreatic Neoplasms (Pancreatic Cancer) 06/14/2009 - "Targeting the EphA2 receptor increases specificity of adenoviral transduction of human pancreatic cancer cells in vitro but fails to enhance pancreatic cancer transduction in vivo." 06/14/2009 - "To generate an adenoviral vector specifically targeting the EphA2 receptor (EphA2R) highly expressed on pancreatic cancer cells in vivo. " 01/01/2006 - "Patterns of EphA2 protein expression in primary and metastatic pancreatic carcinoma and correlation with genetic status." 10/07/2008 - "Effects of dasatinib on EphA2 receptor tyrosine kinase activity and downstream signalling in pancreatic cancer." 01/01/2006 - "We collected clinicopathologic data and paraffin-embedded materials from 98 patients with primary and/or metastatic pancreatic cancer and performed immunohistochemical labeling for EphA2 protein. "
4.	Bites and Stings (Sting) 01/01/2021 - "To develop an effective treatment, we aimed at improving the suboptimal antitumor efficacy of oncolytic adenoviruses (OAs) by testing the combination with a gene-therapy approach using a bispecific T-cell engager (BiTE) directed towards the erythropoietin-producing human hepatocellular carcinoma A2 receptor (EphA2), conveyed by a replication-incompetent adenoviral vector (EphA2 adenovirus (EAd)). "
5.	Neoplasm Metastasis (Metastasis) 09/01/2011 - "The positive rates of EphA2 protein in NPC were 27.27% (3/11) in stage I, 56.25% (9/16) in stage II, 68.19% (15/22) in stage III, and 83.33% (10/12) in stage IV. The positive expressions of EphA2 in T1 + T2 and T3 + T4 with neck lymph node and distant metastasis were 58.33% (7/12) and 88.89% (16/18) respectively, while those in T1 +T2 and T3 + T4 without metastasis were 31.25% (5/16) and 50.00% (6/12) respectively. " 04/01/2021 - "EPHA2 transcript levels are enriched in human breast cancer bone metastatic lesions relative to visceral metastatic sites; EphA2 protein expression was detected in breast tumor cells in bone metastases in patient samples, supporting the clinical relevance of the study's findings. " 03/01/2011 - "The results of this study demonstrate that EphA2 protein expression is significantly increased in LSCC tissues and cell lines, and EphA2 protein overexpression is associated with tumor recurrence, metastasis and poorer prognosis in LSCC patients. " 01/01/2021 - "The EphA2 receptor is a promising drug target for cancer treatment, since EphA2 activation can inhibit metastasis and tumor progression. " 09/01/2011 - "The positive expression of EphA2 protein was correlated with the clinical stage, the neck lymph node metastasis and distant metastasis, and prognosis of NPC, respectively (P < 0.05). "

Related Drugs and Biologics

1.	Erythropoietin
2.	Liposomes (Liposome)
3.	Telmisartan (Micardis)
4.	Peptides (Polypeptides)
5.	Antineoplastic Agents (Antineoplastics)
6.	Gemcitabine
7.	Ligands
8.	Cadherins (E-Cadherin)
9.	Ephrin-A1 (Ephrin A1)
10.	Ephrins

Related Therapies and Procedures

1.	Therapeutics
2.	Ligation
3.	Drug Therapy (Chemotherapy)